Anti-vascular endothelial growth factor and retinopathy of prematurity

British Journal of Ophthalmology

Volumn 92, Issue 11, 2008, Pages 1437-1438

  Sears, Jonathan E ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN;

DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HUMAN; MEDICAL RESEARCH; PREMATURITY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINOPATHY; RETROLENTAL FIBROPLASIA;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; INFANT, NEWBORN; MICE; OXYGEN INHALATION THERAPY; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; RETINOPATHY OF PREMATURITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 55449118425     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2008.141481     Document Type: Editorial

References (20)

1. Ashton N. Pathological basis of retrolental fibroplasias. Br J Ophthalmol 1954;38:385-96.
2. Smith LE, Weslowski E, McClellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994;35:101- 11.
3. Alon T, Hemo I, Pe'er J, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995;1:1024- 28.
4. Pierce EA, Foley ED, Smith LE. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol 1996;114:1219-28.
5. Chen J, Connor KM, Aderman CM, et al. Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest 2008;118:526-33.
6. Lofqvist C, Chen J, Connor KM, et al. From the Cover: IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth. Proc Natl Acad Sci USA 2007;104:10589-94.
7. Chang KH, Chan-Ling T, McFarland EC, et al. IGF binding protein-3 regulates hematopoietic stem cell and endothelial precursor cell function during vascular development. Proc Natl Acad Sci USA 2007;104:10595-600.
8. Chow LC, Wright KW, Sola A. Can changes in clinical practice decrease the incidence of severe retinopathy of prematurity in very low birth weight infants? Pediatrics 2003;111:339-45.
9. Wright KW, Sami D, Thompson L, et al. A physiologic reduced oxygen protocol decreases the incidence of threshold retinopathy of prematurity, Trans Am Ophthalmol Soc 2006;104:78-84.
10. Flynn JT, Bancalari E, Snyder ES, et al. A cohort study of transcutaneous oxygen tension and the incidence and severity of retinopathy of prematurity. N Engl J Med 1992;326:1050-54.
11. Chang TS, Bressler NM, Fine JT, et al. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 2007;125:1460-69.
12. Kaiser PK, Brown DM, Zhank K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 2007;144:850-57.
13. Kusaka S, Chima C, Wada K, et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol 2008;92:1450-6.
14. Aiello LP, Avery RL, Arrig PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-87.
15. Sonniez K, Drenser KA, Capone A Jr, et al. Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology 2008;115:1065-70:e1.
16. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007;114:2179- 82.
17. Pieh C, Agostini H, Buschbeck C, et al. VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity. Br J Ophthalmol 2008;92:689-93.
18. Thebaud B, Ladha F, Michelakis, et al. Vascular endothelial growth factor gene therapy increases survival, promotes lung angiogenesis, and prevents alveolar damage in hyperoxia-induced lung injury: evidence that angiogenesis participates in alveolarization. Circulation 2005;112:2477-86.
19. Geisen P, Peterson LJ, Martiniuk D, et al. Neutralizing antibody to VEGF reduces intravitreous neovascularization and may not interfere with ongoing intraretinal vascularization in a rat model of retinopathy of prematurity. Mol Vis 2008;14:345-57.
20. Chiang MF, Wang L, Busioc M, et al. Telemedical retinopathy of prematurity diagnosis: accuracy, reliability, and image quality. Arch Ophthalmol 2007;125:1531-38.